TranScrip Respiratory

TranScrip has conducted an extensive number of respiratory projects since 2008. It has covered projects ranging from translational medicine, working with mature products and managing the challenges of inhaled generics.  The contracts include supporting major successful MAAs and NDAs, variations and a wide range of expert services in translational medicine and drug development.

Additional therapeutic areas

Infectious Diseases, Oncology, Internal Medicine, CNS/Pain


TranScrip Respiratory Experts

TranScrip’s Respiratory team has worked on all phases of projects ranging from translational programmes involving provision of a complete, virtual biotech team to peri-registration work involving submissions for big pharma. Project size has ranged from provision of therapeutic, operational and / or strategic expertise by individuals through to provision of multifunctional strategic and operational teams of up to 10 people.

Tim Joslin
Head of Respiratory

Tim leads TranScrip's clients' programmes in respiratory product development, registration, and post-licensing.

He has over 30 years' of industry experience covering the complete product  life-cycle from "Target Product Profile" and national/global launches to post-patent strategies for respiratory and other therapeutic areas.

Lars Larsson
Respiratory and Allergy Specialist

Lars is one of TranScrip’s key experts in respiratory, allergic and immunological diseases.

He has more than 40 years’ experience of clinical work in the disease areas, and more than 20 years’ pharma experience covering all stages of global drug development including biopharmaceuticals, MABs and antisense oligonucleotides, systemic as well as inhaled. In addition, he has extensive experience in licensing and evaluation/due diligence of pharma and biotech projects.

Lars became MD at the University of Umeå, Sweden, in 1977 and holds board certificates in Internal Medicine, Pulmonary Medicine and Allergy. He is Associated Professor in Pulmonary Medicine at the University of Umeå. After several years in full time clinical work in internal medicine and respiratory medicine, he joined Astra (later AstraZeneca) in 1995 as medical adviser, and then advanced to head Medical Department at Astra Draco in 1997. In 1999 he moved to Pharmacia Diagnostics AB as VP Medical and Regulatory Affairs and later held positions as VP and CMO at a number of biotech companies, including Biolipox AB and Resistentia, before moving on to his role as Clinical Research Head Cough, Cold and Allergy, at Novartis Consumer health. Most recently he was Executive Medical Director Licensing for Respiratory and Inflammation therapeutic area in AstraZeneca.

During his years in industry, Lars has worked in small start-up biotech companies as well as large pharma companies and has been involved in all stages of drug development of biopharmaceuticals, large molecules and oligonucleotides, including inhaled delivery of large molecules. He has interacted with regulatory authorities in Europe as well as USA and Japan on several occasions, and worked closely with commercial colleagues to find the optimal positioning for novel treatments. He has also organised and participated in numerous advisory boards and KOL meetings, and organised and spoken at company arranged symposia.

Whilst working as CMO in biotech companies, and more recently as a board member, Lars has actively participated in fund raising and IPO processes. As Executive Medical Director Licensing he has also gained a lot of experience in evaluating external projects and closing licensing deals in several therapeutic areas.

Since joining Transcrip in 2013 he  has worked in several small and mid-sized companies designing and executing development programs in respiratory and allergic diseases. The work has included small as well as large molecules and systemic as well as inhaled routes. He has also organised and taken part in authority meetings and KOL ad boards..

Key areas of expertise
1. Drug development
2. Due diligence
3. Inhaled therapeutics

Latest Respiratory News

17 October

ERS 2017 Asthma Back in Focus

At the European Respiratory Society (ERS) Congress September 9 – 12, Milan, there was a renewed interest in asthma, with several new approaches to the treatment of severe asthma being presented. This interest was sparked by new data and events in the asthma space.

Forthcoming Events

There are currently no posts.

Company Product Phase Indication and Service
SME Complement Inhibitors Translational Asthma: Identification and coordination of centres to run phase 1a/1b studies. Developing clinical programme design, managing translational clinical programme and decisions relating to next steps. Regulatory strategy input to support European development in asthma. Providing legal representation and 'responsible' person.
Medium Inhaled LABA & LAMA Phase III Asthma: Support for regulatory and development programmes and the submission dossier and answering specific regulatory questions.
Top 50 CRTH2 Antagonist Phase III Asthma: Support of study feasibility & investigator suitability, study investigator training plan, additional appropriate study sites and creation of contingency plans for patient recruitment and retention.
SME PDE-4 Inhibitor Translational Asthma and COPD: Due diligence on in-license of respiratory portfolio and specific due diligence on a PDE-4 inhibitor.
SME Inhaled IFN Translational Asthma and COPD: Medical director and drug safety management, clinical development operations. Regulatory support for strategic, operational and clinical development activities.
Top 50 Various Translational - Phase III Asthma and IPF: Clinically responsible for development programs, including development of clinical plans, authority contacts etc.
SME CRTH2 Antagonist Translational Asthma and Allergy: Outline regulatory plan for paediatric development, GAP analysis to support paediatric regulatory plan, discussion of GAP analysis and/or clinical development plan with client and preliminary planning of clinical development plan.
Not Pharma Various Translational Asthma and COPD: Due diligence advice in relation to potential investment in drug projects already in clinical development.
Medium Inhaled Device Translational Asthma and/or COPD: Provision of expert support to design a PoC study for potential development of a combination product in an API-activating device.
Medium Inhaled Anticholinergic Phase III COPD: Regulatory support for clinical summary and clinical expert report (2.5).
SME IL8 Antagonist Translational COPD: Oversight of first in man study, creation of IB and clinical trial applications.
Top 50 Inhaled Immunological Mature Pulmonary Arterial Hypertension: Scientific advice for early research and development projects plus mechanism and regulatory, positioning support.
SME Inhaled Product Translational Pulmonary Arterial Hypertension: regulatory project, successfully obtaining orphan drug designation. Managing the regulatory approval to run trials in US and UK, managing the clinical trials and the drug safety database, responsible person and annual reporting.
Medium Surfactant Mature Respiratory Distress Syndrome in Newborns: Risk Management Plan update for an orphan drug in the new regulatory approved format.
Medium Inhaled ICS LABA Translational Acute Respiratory Distress: QC of Common Technical Document Sections (2.7.2, 2.7.3, 2.7.4 and 2.5) and due diligence.
Top 50 Surfactant Translational Acute Respiratory Distress in Neonates: Consultation on clinical development.
Medium Various Mature Respiratory: Assessing and facilitating access to respiratory portfolio for the Japanese and Asian market.
Medium Various Inhaled Phase III Respiratory: support for new inhaled devices.
Top 50 Various Translational Allergy: Evaluation and development plan for approval of a new therapy for allergy.
SME Inhalation Devices Phase III Cystic Fibrosis: Provision of advice on inhaled therapies and inhalation devices.
SME Peptide Translational Cystic Fibrosis: Preparation of a grant submission to the Cystic Fibrosis Foundation.